product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
Human TRAIL R2/TNFRSF10B PE-conjugated Antibody
catalog :
FAB6311P-100
quantity :
100 Tests (also 25 Tests)
price :
429 USD
clonality :
monoclonal
host :
mouse
conjugate :
PE
clone name :
71908
reactivity :
human
application :
western blot, flow cytometry
more info or order :
R&D Systems product webpage
citations: 42
Reference
Romani A, Lodi G, Casciano F, Gonelli A, Secchiero P, Zauli G, et al. Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells. Cells. 2024;13: pubmed publisher
Holmgren C, Sunstr xf6 m Th xf6 rnberg E, Granqvist V, Larsson C. Induction of Breast Cancer Cell Apoptosis by TRAIL and Smac Mimetics: Involvement of RIP1 and cFLIP. Curr Issues Mol Biol. 2022;44:4803-4821 pubmed publisher
Bernareggi D, Xie Q, Prager B, Yun J, Cruz L, Pham T, et al. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. Nat Commun. 2022;13:1899 pubmed publisher
Raman D, Tay P, Hirpara J, Liu D, Pervaiz S. TRAIL sensitivity of nasopharyngeal cancer cells involves redox dependent upregulation of TMTC2 and its interaction with membrane caspase-3. Redox Biol. 2021;48:102193 pubmed publisher
Tufano M, Cesaro E, Martinelli R, Pacelli R, Romano S, Romano M. FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma. Front Cell Dev Biol. 2021;9:718947 pubmed publisher
Ren Y, Wang X, Huang S, Xu Y, Weng G, Yu R. Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis. Front Pharmacol. 2021;12:560903 pubmed publisher
Martini S, Figini M, Croce A, Frigerio B, Pennati M, Gianni A, et al. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. Cells. 2020;9: pubmed publisher
Dittmann J, Haydn T, Metzger P, Ward G, Boerries M, Vogler M, et al. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. Cell Death Differ. 2020;27:1878-1895 pubmed publisher
Jo E, Lee Y, Lee H, Park J, Park H, Choi Y, et al. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. BMC Cancer. 2019;19:496 pubmed publisher
Twomey J, Zhang B. Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model. Cancers (Basel). 2019;11: pubmed publisher
Twomey J, Zhao L, Luo S, Xu Q, Zhang B. Tubulin couples death receptor 5 to regulate apoptosis. Oncotarget. 2018;9:36804-36815 pubmed publisher
Xu S, Li D, Li T, Qiao L, Li K, Guo L, et al. miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin. Cell Physiol Biochem. 2018;51:2212-2223 pubmed publisher
Lian B, Yang D, Liu Y, Shi G, Li J, Yan X, et al. miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis. Cell Physiol Biochem. 2018;49:2151-2162 pubmed publisher
You C, Yang Y, Gao B. Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity. Cell Physiol Biochem. 2018;49:235-244 pubmed publisher
Bozza W, Zhang Y, Zhang B. Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis. Oncotarget. 2018;9:23264-23273 pubmed publisher
Zhao Y, Tian B, Wang Y, Ding H. Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5. Med Sci Monit. 2017;23:5096-5105 pubmed
Jaworska D, Szliszka E. Targeting Apoptotic Activity Against Prostate Cancer Stem Cells. Int J Mol Sci. 2017;18: pubmed publisher
Singh H, Otano I, Rombouts K, Singh K, Peppa D, Gill U, et al. TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Sci Rep. 2017;7:5514 pubmed publisher
Dimberg L, Towers C, Behbakht K, Hotz T, Kim J, Fosmire S, et al. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017;15:382-394 pubmed publisher
Warat M, Sadowski T, Szliszka E, Krol W, Czuba Z. The role of selected flavonols in tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) expression on activated RAW 264.7 macrophages. Molecules. 2015;20:900-12 pubmed publisher
Chen J, Bozza W, Di X, Zhang Y, Hallett W, Zhang B. H-Ras regulation of TRAIL death receptor mediated apoptosis. Oncotarget. 2014;5:5125-37 pubmed
Warat M, Szliszka E, Korzonek Szlacheta I, Krol W, Czuba Z. Chrysin, apigenin and acacetin inhibit tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) on activated RAW264.7 macrophages. Int J Mol Sci. 2014;15:11510-22 pubmed publisher
Zauli G, Celeghini C, Monasta L, Martinelli M, Luppi S, Gonelli A, et al. Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. Reproduction. 2014;148:191-8 pubmed publisher
Calzolari A, Saulle E, De Angelis M, Pasquini L, Boe A, Pelacchi F, et al. Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS ONE. 2014;9:e94438 pubmed publisher
Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, et al. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res. 2014;34:729-34 pubmed
Kim S, Woo J, Jeong C, Ryu C, Jang J, Jeun S. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med. 2014;3:172-82 pubmed publisher
Gupta S, Francis S, Nair M, Mo Y, Aggarwal B. Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-C. J Biol Chem. 2013;288:32343-56 pubmed publisher
Di X, Zhang G, Zhang Y, Takeda K, Rivera Rosado L, Zhang B. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget. 2013;4:1349-64 pubmed
Gojo I, Tan M, Fang H, Sadowska M, Lapidus R, Baer M, et al. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res. 2013;19:1838-51 pubmed publisher
Hong S, Kim H, Kim J, Ha H, Kim Y, Bae E, et al. Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. J Biol Chem. 2013;288:3560-70 pubmed publisher
Peppa D, Gill U, Reynolds G, Easom N, Pallett L, Schurich A, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med. 2013;210:99-114 pubmed publisher
Chen J, Shen H, Rivera Rosado L, Zhang Y, Di X, Zhang B. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget. 2012;3:833-42 pubmed
Kalb M, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-?-mediated antitumor reactivity. J Immunol. 2012;188:1583-91 pubmed publisher
Garimella S, Rocca A, Lipkowitz S. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res. 2012;10:75-85 pubmed publisher
Rauert H, Stühmer T, Bargou R, Wajant H, Siegmund D. TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis. 2011;2:e194 pubmed publisher
Szliszka E, Helewski K, Mizgala E, Krol W. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int J Oncol. 2011;39:771-9 pubmed publisher
Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011;17:3181-92 pubmed publisher
Zhang B, Shan H, Li D, Li Z, Zhu K, Jiang Z, et al. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5. Oncol Rep. 2011;25:461-8 pubmed publisher
Kim S, Lim J, Park S, Jeong C, Oh J, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008;68:9614-23 pubmed publisher
Secchiero P, Melloni E, Corallini F, Beltrami A, Alviano F, Milani D, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells. 2008;26:2955-63 pubmed publisher
Wu C, Kao C, Safa A. TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Hum Gene Ther. 2008;19:731-43 pubmed publisher
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy P, Lampertico P, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007;204:667-80 pubmed
product information
brand :
R&D Systems
master code :
FAB6311P
SKU :
FAB6311P-100
product name :
Human TRAIL R2/TNFRSF10B PE-conjugated Antibody
unit size :
100 Tests (also 25 Tests)
seo description :
The Human TRAIL R2/TNFRSF10B PE-conjugated Antibody from R&D Systems is a mouse monoclonal antibody to TRAILR2/TNFRSF10B. This antibody reacts with human,mouse,rat. The Human TRAIL R2/TNFRSF10B PE-conjugated Antibody has been validated for the following applications: Flow Cytometry,Western Blot.
target :
TRAIL R2/TNFRSF10B
category :
Primary Antibodies
buffer :
Supplied in a saline solution containing BSA and Sodium Azide.
clonality :
Monoclonal
clone :
71908
conjugate :
Phycoerythrin
dilution :
Flow Cytometry 10 uL/10^6 cells
host :
Mouse
immunogen :
Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B, Ile56-Glu182, Accession # O14763
isotype :
IgG2b
purity :
Protein A or G purified from hybridoma culture supernatant
species :
Human,Mouse,Rat
specificity :
Detects human TRAIL R2 in direct ELISAs and Western blots. In direct ELISAs, does not cross-react with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or recombinant mouse TRAIL R2.
gene symbol :
TNFRSF10B
top caption :
MDA-MB-231 Human Cell Line by Flow Cytometry.
accessionNumbers :
O14763
applications :
Flow Cytometry,Western Blot
USD :
429 USD
alt names :
CD262, CD262 antigen, death domain containing receptor for TRAIL/Apo-2L, Death receptor 5, DR5, DR5TRICK2B, Fas-like protein, KILLER/DR5, KILLERapoptosis inducing protein TRICK2A/2B, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TRAIL receptor 2, TRAILR2, TRAIL-R2apoptosis inducing receptor TRAIL-R2, TRAILR2cytotoxic TRAIL receptor-2, TRICK2, TRICK2A, TRICKB, tumor necrosis factor receptor superfamily member 10B, tumor necrosis factor receptor superfamily, member 10b, tumor necrosis factor receptor-like protein ZTNFR9, ZTNFR9
storage :
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 ░C as supplied.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.